By Dennis Thompson HealthDay ReporterWEDNESDAY, Jan. 7, 2026 (HealthDay News) — Ozempic and Wegovy might help people avoid ...

Chronic inflammatory bowel disease is challenging to treat and carries a risk of complications, including the development of bowel cancer. Young people are particularly affected: when genetic ...

The study included 30 participants between the ages 50-78, all overweight or obese (a cancer risk) yet healthy otherwise.

A research team at Queen’s University is seeking to understand how bowel cancer develops resistance to treatments including ...

The incidence of early-onset colorectal cancer has been increasing worldwide, a trend that has coincided with growing intake ...

Doctors are seeing colon cancer in people in their 20s and 30s. New research suggests it starts in infancy.

GLP-1 receptor agonists like Ozempic and Wegovy may increase survival among patients with colon cancer, reported a new study published in Cancer Investigation. GLP-1 receptor agonists were originally ...

Biologist Eduard Batlle used to spend his weekends at his parents’ confectionery. Now he’s one of the six inventors of ...

Almost 2 million people are diagnosed with bowel cancer each year. Also known as colorectal cancer, it’s the third most common cancer worldwide. While the majority of people diagnosed with bowel ...

Innovent Biologics has received China’s NMPA approval for the NDA for Tabosun, a CTLA-4 monoclonal antibody for colon cancer.